Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
This disclosure teaches phospholipid nanoparticle compositions of cannabinoids formed from phospholipids and simpler lipids in an unfired sequential process that encapsulate a high concentration of cannabinoids, and create standardized precision-metered dosage forms of cannabinoids; yielding an increase cannabinoid transport across hydrophobic mucosa; increase the bioavailability of the cannabinoid 2-fold to 8-fold, decrease the dose of cannabinoids 2-fold to 8-fold less than an amount of cannabinoids needed to illicit the same therapeutic effect compared to raw and non-encapsulated cannabinoids; where the nanoparticle dynamic structure reduces the adverse effects of cannabinoids; and enable safe more efficacious cannabinoid therapy.
1. A drug delivery system comprising nanoparticle structures;
wherein a single layer of essential phospholipids encapsulates liquid lipids and cannabinoids in each nanoparticle structure; wherein the phospholipid content (weight/volume) of the nanoparticle structures is 5-30%;
wherein the nanoparticle structures have a particle size distribution from 50 to 150 nm; and
wherein the nanoparticle structures yield standardized precision-metered dose cannabinoids.
2. The drug delivery system of claim 1 , wherein the essential phospholipids are comprised of greater than 85% phosphatidylcholine.
3. The drug delivery system of claim 1 , wherein the nanoparticle structures do not contain surfactants.
4. The drug delivery system of claim 1 , wherein the nanoparticle structures can be administered via the sublingual mucosa and buccal mucosa of a mammal.
5. The drug delivery system of claim 1 , wherein the nanoparticle structures can be administered across dermal and epidermal barriers.
6. The drug delivery system of claim 1 , wherein the nanoparticle structures can be administered across nasal mucosal barriers.
7. The drug delivery system of claim 1 , wherein the nanoparticle structures can be administered across the intestinal mucosal barriers.
8. The drug delivery system of claim 1 , wherein the nanoparticle structures are composed of an outer phospholipid membrane and adjustable viscoelastic gel lipid core.
9. The drug delivery system of claim 1 ; wherein the nanoparticle increases the bioavailability of the cannabinoid 2-fold to 8-fold compared to bioavailability without nanoparticle encapsulation.
10. The drug delivery system of claim 1 ; wherein the nanoparticle structures decrease the dose of cannabinoids 2-fold to 8-fold less than an amount of cannabinoids needed to elicit the same therapeutic effect compared to raw and non-encapsulated cannabinoids in a patient in need thereof.
11. The drug delivery system of claim 1 ; wherein the nanoparticle structures reduce the adverse effects of cannabinoids compared to adverse effects of cannabinoids without nanoparticle encapsulation.
12. A method of cannabinoid therapy comprising administering to a mammal a phospholipid nanoparticle structure; wherein cannabinoids are encapsulated in the nanoparticle structure; wherein a single layer of essential phospholipids encapsulates liquid lipids and the cannabinoids in the nanoparticle structure; wherein the phospholipid content (weight/volume) of the nanoparticle structure is 5-30%; wherein the nanoparticle structure has a particle size distribution from 50 to 150 nm; wherein the nanoparticle structure yields standardized precision-metered dose cannabinoids.
13. The method of claim 12 wherein the therapeutic activity of cannabinoids is increased; and wherein cannabinoid adverse effects are reduced.